- Home
- IKT vs CCIF Comparison
IKT vs CCIF Comparison
Compare IKT & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- CCIF
- Stock Information
- Founded
- IKT 2008
- CCIF 2011
- Country
- IKT United States
- CCIF United States
- Employees
- IKT N/A
- CCIF N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- CCIF Finance/Investors Services
- Sector
- IKT Health Care
- CCIF Finance
- Exchange
- IKT Nasdaq
- CCIF Nasdaq
- Market Cap
- IKT 111.8M
- CCIF 110.4M
- IPO Year
- IKT 2020
- CCIF N/A
- Fundamental
- Price
- IKT $1.53
- CCIF $5.17
- Analyst Decision
- IKT Hold
- CCIF
- Analyst Count
- IKT 1
- CCIF 0
- Target Price
- IKT N/A
- CCIF N/A
- AVG Volume (30 Days)
- IKT 109.4K
- CCIF 76.9K
- Earning Date
- IKT 11-14-2025
- CCIF 01-01-0001
- Dividend Yield
- IKT N/A
- CCIF 25.90%
- EPS Growth
- IKT N/A
- CCIF N/A
- EPS
- IKT N/A
- CCIF N/A
- Revenue
- IKT N/A
- CCIF N/A
- Revenue This Year
- IKT N/A
- CCIF N/A
- Revenue Next Year
- IKT N/A
- CCIF N/A
- P/E Ratio
- IKT N/A
- CCIF N/A
- Revenue Growth
- IKT N/A
- CCIF N/A
- 52 Week Low
- IKT $1.33
- CCIF $7.43
- 52 Week High
- IKT $4.20
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- IKT 47.90
- CCIF 37.21
- Support Level
- IKT $1.55
- CCIF $5.13
- Resistance Level
- IKT $1.67
- CCIF $5.27
- Average True Range (ATR)
- IKT 0.13
- CCIF 0.09
- MACD
- IKT 0.01
- CCIF 0.01
- Stochastic Oscillator
- IKT 51.16
- CCIF 19.23
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.